CLDN3 and prostate neoplasm: We observed that CLDN3 was silenced in the cell line recapitulating a more aggressive and therapy-resistant stage of prostate tumors (abl), but it was expressed in androgen sensitive prostate cancer cells (LNCaP), representing initial stages of prostate cancer development.